CIK 0001738021 · Non-accelerated filer<br>Smaller reporting company
Compass Therapeutics, Inc.
Sign in to watch- Ticker
- CMPX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-500-8099
- Business address
- 80 GUEST STREET, BOSTON, MA, 02135
- Former names
- Olivia Ventures, Inc.
- Open-market buys, last 90 days
- $21,250
- in 2 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$21,250. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-01-02 | GORDON CARL L Director | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2026-01-02 | Ferneau Philip Director | Grant or award · Stock Option (Right to Buy) | +90,000 | 90,000 | ||
| 2026-01-02 | Anderman Jonathan General Counsel | Grant or award | +150,000 | $5.17 | $776K | 171,000 |
| 2026-01-02 | Anderman Jonathan General Counsel | Grant or award · Stock Option (Right to Buy) | +720,000 | 720,000 | ||
| 2025-11-16 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Shares withheld for taxes | −44,025 | $4.83 | $213K | 6,436,800 |
| 2025-05-27 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Purchase | +10,000 | $2.11 | $21K | 6,480,825 |
| 2025-04-09 | GORDON CARL L Director | Sale | −3,571,428 | $1.59 | $5.7M | 0 |
| 2025-04-09 | ORBIMED ADVISORS LLC Director | Sale | −3,571,428 | $1.59 | $5.7M | 0 |
| 2025-04-07 | Anderman Jonathan Gen Counsel & Corporate Sec | Purchase | +20,000 | $1.54 | $31K | 21,000 |
| 2025-04-07 | Lerner Neil CHIEF ACCOUNTING OFFICER | Purchase | +20,000 | $1.42 | $28K | 320,000 |
| 2025-02-11 | Shin Barry CFO | Grant or award · Stock Option (Right to Buy) | +250,000 | 250,000 | ||
| 2025-02-11 | Schuetz Thomas J. CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +1,500,000 | 1,500,000 | ||
| 2025-02-11 | LINDAHL RICHARD S Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2025-02-11 | Lerner Neil SVP, CAO | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2025-02-11 | GRAY MARY ANN Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2025-02-11 | Ferneau Philip Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2025-02-11 | Chiniara Ellen Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2025-02-11 | Anderman Jonathan Sr VP, Gen Counsel & Corp Sec | Grant or award · Stock Option (Right to Buy) | +280,000 | 280,000 | ||
| 2025-02-11 | GORDON CARL L Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2025-02-11 | Boylan James P Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 |
Page 2 of 8 · 143 trades